tazemetostat

View All

mRNA
Biogen buys Nightstar; Pacira acquires Myoscience; Horizon Pharma announces pricing; STAT with Slingshot Insights; Epizyme announces Equity Offering

Biogen to buy Nightstar for USD 800 Million Biogen known for its efforts in treatments of multiple sclerosis and spinal muscular atrophy wound up the deal to buy Nightstar. The deal will let Biogen have access to two experimental gene therapies for blindness-causing diseases helping Biogen’s pipeline. Pacira...

Find More

Companion Diagnostics
Notizia

Novartis comes up with an answer for breast cancer with PI3K drug alpelisib Novartis comes up with an answer with its recent data on BYL719 (alpelisib) in combination with fulvestrant. Their alpha-specific drug for PIK3CA mutated HR+/HER2- advanced breast cancer, BYL719 plus fulvestrant nearly doubled the progressio...

Find More

transthyretin amyloidosis
Notizia

The interleukin-33 antibody of AnaptysBio passes midstage test in asthma The pipeline drug, etokimab of AnaptysBio, has positive data in a third indication that adds asthma to one of its triumphs. The US-based company gets another proof-of-concept study for the interleukin-33 (IL-33) inhibitor, because of phase 2a ...

Find More